Japan solid dose market predicted to bloom in 201921 Feb 2019
Executives predict Japan to be the second fastest growing mature market for solid dose drugs in 2019, and the second fastest overall country for biologicals growth.
A new report published ahead of CPhI Japan 2019 says tThe Japanese pharma market is expected to grow quickly in 2019.
The trade exhibition (18-20 March, 2019) will open its doors to 20,000 pharma professionals, as industry executives predict Japan to be the second fastest growing mature market for solid dose drugs in 2019, and even more impressively, the second fastest overall country for biologicals growth – finishing only narrowly behind the US.
The findings represent a sizable year-on-year improvement in outlook for pharma in Japan, with expected growth of solid dose formulations improving by more than 10%, with generic drug classes highlighted as offering strong growth prospects. Significantly, it now ranks ahead of all EU nations and Korea – finishing only behind the US of the mature pharma markets.
Laura Murina, Brand Manager CPhI Japan, said: “Japan’s pharmaceutical industry has long centred on strong innovation and patented drugs, but we are now observing a dramatic increase in generics and biosimilars in the market.”
The outlook for the biologics sector was even more positive, where growth potential for Japan (7.5) was second only to the US (7.9) – recognising the substantial potential for biosimilars in 2019 and beyond – as a result, the collocated BioPh has become a much larger part of CPhI Japan in recent years.
Japanese companies reported renewed confidence in the domestic market, but more significantly, a larger number are also exploring exports than in previous years. In fact, 2019 will be the first year that Japan’s largest pharma companies gain 50% of their sales from overseas – as recently as 2017 this was still well under 50%, but it has grown quickly in recent years.
Crucially, this internalisation is being observed both ways – inbound and outbound – and is highlighted on the CPhI Japan exhibition floor. In total, more than 20,000 executives will attend, with more than 60 countries represented, and over 550 exhibitors – an increase of over 100 exhibitors in just the last three years alone. These include major suppliers of pharmaceutical ingredients, packaging, contract services, as well as machinery, technology, and new for 2019, digital and IT companies in the Pharma IT & Digital Expo. Another industry segment offering opportunities are nutraceuticals and traditional Chinese medicines (known as Kampo by Japanese consumers). In response, CPhI Japan has launched a new Natural Extracts zone.
The report suggested that the resurgence in international interest is being driven by de-regulation opening up accelerated approval pathways, coupled with one of the world’s fastest-growing generics markets. R&D in Japan also remains at the forefront of global pharma – a result of both the attractiveness of the nation’s medicines market and the strength of local research institutions.
Nobuaki Nito, General Manager UBM Japan, added: “What is most exciting, is that with international collaborations increasing, there are clearly now more partnering opportunities in the market than ever before, which is why it is such a good time to attend CPhI Japan.”
Beyond the exhibition, over 9,000 pharma professionals will attend the CPhI Japan Conference, with insights from The International Federation of Pharmaceutical Manufacturers & Associations（IFPMA), the Japan Pharmaceutical Traders’ Association, as well as industry executives from big pharma, generics and bio. With the government pursuing policies anticipated to grow generics to 80% market share by September 2020, one of the major challenges for the industry will be sourcing a stable supply of APIs and this will form an integral part of the 2019 conference agenda. Other sessions will explore the issues and opportunities for parallel approvals (PMDA alongside FDA or EU) and biosimilar growth strategies.
The report concludes that Japan is a country ripe for growth across a number of product classes, but the long-term winners of regulatory changes, aging demographics and innovative R&D remain hard to pick. What is clear, however, is that the opportunities have widened quickly, and new players would be wise to act fast. In particular, there are renewed opportunities for international contract service providers, generics and finished drug manufacturers as well as domestic manufacturers to become the local manufacturing arms of international firms.
Third Sartorius Research Xchange Forum 2019 focuses on CAR-T cell therapy
13 Mar 2019
Event for experts from academia and industry, including talks, live demo sessions, and panel discussion.Read more
Overcoming lyophilization challenges at Interphex 2019
10 Mar 2019
Line of Sight approach to freeze-drying enables organizations to bring pharmaceutical products safely and quickly to market.Read more
'Tamper-evident' benefits are evident
28 Feb 2019
2019 will mark Uniplast's debut at this year's edition of CPhI Worlwide in Frankfurt, where it will showcase its expertise in plastic packaging.Read more
Pharma in South East Asia booming as CPhI opens event for the first time in Thailand
27 Feb 2019
Healthcare and pharmaceutical reforms, designed to increase access to high-value medicines, driving growth.Read more
Pharmapack Europe 2019 Award Winners
7 Feb 2019
Awards showcased a wide range of industry-changing discoveries in drug delivery, packaging and automation.Read more
Pharmapack report predicts diversification of innovation leading to a rise in licensing and partnering
27 Jan 2019
New report highlights Germany, France and Switzerland as tier-one nations for ‘drug delivery innovation’, and warns the challenge will be to scale-up and approve promising prototypes.Read more
Fiera Milano to host CPhI Worldwide 2020
20 Jan 2019
The exhibition district will see the world's largest pharma industry event.Read more
BASF’s new active ingredients target skin conditions’ root causes
15 Jan 2019
New active ingredients coming from the research of BASF’s innovation platforms on epigenetics, microbiome and extraction.Read more
Future-oriented packaging concepts from Sanner
11 Dec 2018
Company will showcase a range of packaging solutions, from desiccant and customized packaging to smart packaging solutions, at Pharmapack.Read more
India to have strongest global growth in 2019?
4 Dec 2018
Main drivers cited as ‘high-growth domestic market’ and ‘expanding manufacturing exports’.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation